Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)
- Status
- COMPLETED
- Phase
- PHASE2
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
- Status
- COMPLETED
- Phase
- PHASE2
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas
- Status
- UNKNOWN
- Phase
- PHASE2
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
- Status
- WITHDRAWN
- Phase
- PHASE2
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2